Krieger D T, Howanitz P J, Frantz A G
J Clin Endocrinol Metab. 1976 Feb;42(2):260-72. doi: 10.1210/jcem-42-2-260.
The mean prolactin concentration during sleep and the per cent change (increase) and increment in the nocturnal elevation of plasma prolactin concentrations were significantly reduced (P less than .01, less than .01, and less than .001, respectively) in 6 untreated patients with clinically active Cushing's disease, compared with concentrations seen in normal subjects. There was no significant difference between mean-awake and mean-sleep plasma prolactin concentration in these patients, in contrast to that seen in normal subjects. In contrast, patients with hypercorticism secondary to adrenal adenoma (n = 2) or receiving long-term, high-dose corticosteroid therapy (n = 6) did not differ significantly from normal subjects in the percentage change seen in the nocturnal elevation of their plasma prolactin concentrations. Although mean prolactin concentration during sleep was reduced in these two categories of hypercorticism, a significant difference was still present between mean-awake and mean-sleep plasma prolactin concentration. (The nocturnal increment in plasma prolactin concentrations in these patients with hypercorticism compared with that of normal subjects was reduced, P less than .02). The difference between the percentage change and nocturnal increment observed in patients with Cushing's disease versus that seen in these two categories of hypercorticism was significant at P less than .02 and P less than .01, respectively. Four untreated patients with localized hypothalamic tumors also showed a significant reduction in the percentage change and increment in the nocturnal elevation of plasma prolactin concentrations (P less than .05 and P less than .02). In contrast to these findings, the prolactin responses to thyrotropin-releasing hormone (indicative of pituitary responsiveness) in patients with Cushing's disease, patients with adrenal adenoma, or those receiving chronic corticosteroid therapy, were all within the normal range seen in sex-matched control subjects. These findings provide additional evidence for the suggestion that there is altered hypothalamic function in patients with Cushing's disease.
与正常受试者相比,6例未经治疗的临床活动性库欣病患者睡眠期间的平均催乳素浓度、血浆催乳素浓度夜间升高的百分比变化(增加)和增量均显著降低(分别为P<0.01、<0.01和<0.001)。与正常受试者不同,这些患者清醒时和睡眠时的平均血浆催乳素浓度无显著差异。相比之下,肾上腺腺瘤继发皮质醇增多症患者(n=2)或接受长期大剂量皮质类固醇治疗的患者(n=6),其血浆催乳素浓度夜间升高的百分比变化与正常受试者无显著差异。虽然这两类皮质醇增多症患者睡眠期间的平均催乳素浓度降低,但清醒时和睡眠时的平均血浆催乳素浓度仍存在显著差异。(与正常受试者相比,这些皮质醇增多症患者血浆催乳素浓度的夜间增量降低,P<0.02)。库欣病患者与这两类皮质醇增多症患者在百分比变化和夜间增量方面的差异分别为P<0.02和P<0.01,具有显著性。4例未经治疗的局限性下丘脑肿瘤患者血浆催乳素浓度夜间升高的百分比变化和增量也显著降低(P<0.05和P<0.02)。与这些发现相反,库欣病患者、肾上腺腺瘤患者或接受慢性皮质类固醇治疗的患者对促甲状腺激素释放激素的催乳素反应(提示垂体反应性)均在性别匹配的对照受试者的正常范围内。这些发现为库欣病患者下丘脑功能改变的观点提供了更多证据。